| Fathers Suffer Post-Partum Depression More than one in 10 fathers become depressed after the birth of their child, and their postpartum depression is linked to greater risk of the mother developing depression. online.wsj.com |
Magic Formula Investing: Top 10 Fastest Growing Companies Steve Alexander submits:No metric is more loved on Wall Street than revenue growth rates. The pace of revenue growth is usually a major factor in the valuation assigned to a given company. Analysts routinely "pooh-pooh" quarterly earnings per share beats that are accomplished through cost cutting or share buybacks rather than top-line (sales) growth.To a large extent, this is understandable. The life blood of any company is sales. There is a limited amount of growth that can be extracted through cost controls, reflected by the old business wisdom that "you can't cost cut your way to prosperity!". The very best stock opportunities are those with significant revenue growth potential that can achieve that growth with relatively little capital investment, and where the stock can be bought at a reasonable price.Complete Story » seekingalpha.com |
Savient Pharmaceuticals, Inc Q2 2010 Earnings Call Transcript Savient Pharmaceuticals, Inc. (SVNT)Q2 2010 Earnings CallAugust 4, 2010 9:00 am ETComplete Story » seekingalpha.com |
What Medicare Will Ask About Dendreon's Provenge Pharmalot submits: There is yet another twist in the ongoing and always interesting Provenge saga. The Centers for Medicare & Medicaid Services, which last June issued a surprise decision to conduct a National Coverage Analysis, which will be used for coverage guidance by Medicare contractors, has released the questions to be answered at a Nov. 17 panel meeting and the focus is on on-label efficacy. The NCA, for those who may not recall, stunned all sorts of people because such reviews do not occur very often (see here and here). Dendreon (DNDN) execs subsequently downplayed the move by telling analysts NCA was sparked by concerns of off-label use, although CMS has been cryptic about its reasoning other than to point to the fact that Provenge is the first in a new class of treatments that use a patient’s own cells to stimulate the body’s immune system in an approach known as immunotherapy.Complete Story » seekingalpha.com |
Insurer Alters Way to Pay Cancer Docs In the latest experiment aimed at curbing health-care costs, UnitedHealth Group is altering the way cancer specialists are paid. online.wsj.com |